Mabwell Biotech is a Chinese innovative biopharmaceutical company.
Mabwell Biotech is a Chinese innovative biopharmaceutical company based in Shanghai Zhangjiang Hi-Tech Park. Since its establishment in 2017, it has absorbed and newly established nine biopharmaceutical R&D and production enterprises. At present, the company focuses on the development and manufacturing of macromolecular drugs such as therapeutic monoclonal antibodies and long-acting recombinant proteins. There are more than thirty varieties of drugs at different stages of development covering tumor, autoimmunity, anti-infection and ophthalmic diseases. Among them, six of them have entered the clinical stage, and three of them are in Phase III clinical trials.
| Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
|---|---|---|---|---|---|---|
| Apr 29, 2020 | Series A | $278.50M | 9 |
Shiyu Capital
|
— | Detail |
| Investor Name | Lead Investor | Funding Round |
|---|---|---|
Shiyu Capital
|
Yes | Series A |
Haitong Leading Capital Management
|
— | Series A |
Founder H Fund
|
— | Series A |
Huajin Capital
|
— | Series A |
Huarong Rongde Asset Management
|
— | Series A |
Loyal Valley Capital
|
— | Series A |
Oriental Fortune Capital
|
— | Series A |
Sincere Capital
|
— | Series A |
Winfast Holding
|
— | Series A |